A basic requirement for the oral administration of drugs is the substance’s oral bioavailability. If a substance cannot enter the bloodstream via the gastrointestinal tract, or if only a limited amount of the substance reaches the bloodstream, it is not available to take effect in the body. As a result, pharmaceutical companies have gone to great lengths to improve the bioavailability of medications. In some cases, though, these efforts are not necessary. The drug Neupro® from UCB, for example, is the first drug in the world that is only available as a transdermal patch. The active substance in Neupro®, rotigotine, has shown exceptional efficacy in the treatment of Parkinson’s disease. Since rotigotine has practically no bioavailability when taken orally, it cannot be administered as tablets or capsules. Neupro® TTS patches developed and manufactured by LTS not only offer an elegant and practical solution to treatment, it also makes it possible to use rotigotine in the treatment of Parkinson’s disease for the very first time.